Heterogeneous associations of polyomaviruses and herpesviruses with allergy-related phenotypes in childhood.
Journal
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
02
2021
revised:
12
04
2021
accepted:
16
04
2021
pubmed:
26
4
2021
medline:
15
9
2021
entrez:
25
4
2021
Statut:
ppublish
Résumé
Evidence suggests a complex interplay between infections and allergic diseases. To explore the association of 14 common viruses with eczema, asthma, and rhinoconjunctivitis in childhood. We used cross-sectional (n = 686) and prospective (n = 440) data from children participating in the Rhea birth cohort. Immunoglobulin G to polyomaviruses (BK polyomavirus, JC polyomavirus, KI polyomavirus [KIPyV], WU polyomavirus [WUPyV], human polyomavirus 6, human polyomavirus 7, Trichodysplasia spinulosa polyomavirus, Merkel cell polyomavirus, human polyomavirus 9, and human polyomavirus 10) and herpesviruses (Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus-1, Herpes simplex virus-2) were measured at age 4 years by fluorescent bead-based multiplex serology. Definitions of eczema, asthma, and rhinoconjunctivitis at ages 4 and 6 years were based on questionnaires. Mediation of the associations by immune biomarkers was tested. Less likely to have eczema at age 4 years were KIPyV-seropositive (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.27-0.82) and human polyomavirus 6 (OR, 0.44; 95% CI, 0.26-0.73) compared with their seronegative counterparts. Seropositivity to Epstein-Barr virus was negatively associated with eczema at age 4 years (OR, 0.39; 95% CI, 0.22-0.67) and 6 years (OR, 0.50; 95% CI, 0.25-0.99). Children with a higher burden of herpesviruses or of skin polyomaviruses had the lowest odds of eczema at age 4 years. Higher odds for asthma at age 4 years were found for WUPyV-seropositive children (OR, 3.98; 95% CI, 1.38-11.51), and for children seropositive to both respiratory polyomaviruses (KIPyV and WUPyV) (OR, 7.35; 95% CI, 1.66-32.59) compared with children seronegative to both. No associations were observed for rhinoconjunctivitis. There was no evidence of mediation by immune biomarkers. A heterogeneous pattern of infections and allergic diseases was observed with common infections associated with a decreased eczema risk and an increased asthma risk in children.
Sections du résumé
BACKGROUND
Evidence suggests a complex interplay between infections and allergic diseases.
OBJECTIVE
To explore the association of 14 common viruses with eczema, asthma, and rhinoconjunctivitis in childhood.
METHODS
We used cross-sectional (n = 686) and prospective (n = 440) data from children participating in the Rhea birth cohort. Immunoglobulin G to polyomaviruses (BK polyomavirus, JC polyomavirus, KI polyomavirus [KIPyV], WU polyomavirus [WUPyV], human polyomavirus 6, human polyomavirus 7, Trichodysplasia spinulosa polyomavirus, Merkel cell polyomavirus, human polyomavirus 9, and human polyomavirus 10) and herpesviruses (Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus-1, Herpes simplex virus-2) were measured at age 4 years by fluorescent bead-based multiplex serology. Definitions of eczema, asthma, and rhinoconjunctivitis at ages 4 and 6 years were based on questionnaires. Mediation of the associations by immune biomarkers was tested.
RESULTS
Less likely to have eczema at age 4 years were KIPyV-seropositive (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.27-0.82) and human polyomavirus 6 (OR, 0.44; 95% CI, 0.26-0.73) compared with their seronegative counterparts. Seropositivity to Epstein-Barr virus was negatively associated with eczema at age 4 years (OR, 0.39; 95% CI, 0.22-0.67) and 6 years (OR, 0.50; 95% CI, 0.25-0.99). Children with a higher burden of herpesviruses or of skin polyomaviruses had the lowest odds of eczema at age 4 years. Higher odds for asthma at age 4 years were found for WUPyV-seropositive children (OR, 3.98; 95% CI, 1.38-11.51), and for children seropositive to both respiratory polyomaviruses (KIPyV and WUPyV) (OR, 7.35; 95% CI, 1.66-32.59) compared with children seronegative to both. No associations were observed for rhinoconjunctivitis. There was no evidence of mediation by immune biomarkers.
CONCLUSION
A heterogeneous pattern of infections and allergic diseases was observed with common infections associated with a decreased eczema risk and an increased asthma risk in children.
Identifiants
pubmed: 33895421
pii: S1081-1206(21)00302-1
doi: 10.1016/j.anai.2021.04.019
pmc: PMC8801162
mid: NIHMS1759227
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-199.e3Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES007048
Pays : United States
Informations de copyright
Copyright © 2021 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
Clin Exp Allergy. 2009 Apr;39(4):509-17
pubmed: 19055650
J Allergy Clin Immunol. 2002 Nov;110(5):811-3
pubmed: 12417894
J Allergy Clin Immunol. 2019 Jan;143(1):26-35
pubmed: 30476499
Semin Immunopathol. 2020 Feb;42(1):61-74
pubmed: 31989228
J Allergy Clin Immunol. 2001 Apr;107(4):567-74
pubmed: 11295640
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
J Allergy Clin Immunol. 2010 Feb;125(2):433-8
pubmed: 19963258
BMC Health Serv Res. 2017 Mar 14;17(1):201
pubmed: 28288628
Lancet Respir Med. 2014 Feb;2(2):131-40
pubmed: 24503268
Emerg Infect Dis. 2008 Nov;14(11):1766-8
pubmed: 18976566
Clin Exp Allergy. 2020 Apr;50(4):499-507
pubmed: 32037652
Curr Probl Dermatol. 2011;41:1-34
pubmed: 21576944
BMC Pulm Med. 2011 May 14;11:24
pubmed: 21569568
Emerg Infect Dis. 2012 Oct;18(10):1580-8
pubmed: 23017213
Front Cell Infect Microbiol. 2018 May 25;8:177
pubmed: 29888215
Front Pediatr. 2019 Mar 19;7:72
pubmed: 30941335
Psychol Methods. 2013 Jun;18(2):137-50
pubmed: 23379553
Allergy Asthma Proc. 2011 Nov-Dec;32(6):56-62
pubmed: 22221431
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Med Microbiol Immunol. 2012 Feb;201(1):17-23
pubmed: 21614514
BMJ. 2000 Feb 12;320(7232):412-7
pubmed: 10669445
Emerg Infect Dis. 2008 Nov;14(11):1787-9
pubmed: 18976572
J Allergy Clin Immunol. 2007 Sep;120(3):673-9
pubmed: 17586034
Pediatr Allergy Immunol. 1997 May;8(2):91-6
pubmed: 9617779
Am J Epidemiol. 2016 Apr 1;183(7):671-9
pubmed: 26968942
Front Pediatr. 2018 Aug 17;6:228
pubmed: 30175090
J Allergy Clin Immunol. 2020 Sep;146(3):555-570
pubmed: 32320734
Br J Dermatol. 2020 Jun;182(6):1331-1342
pubmed: 31677162
Int Arch Allergy Appl Immunol. 1984;75(2):179-83
pubmed: 6088400
J Invest Dermatol. 2017 Dec;137(12):2460-2461
pubmed: 29169458
BMJ. 1997 Apr 5;314(7086):999-1003
pubmed: 9112843
Am J Epidemiol. 2010 Dec 15;172(12):1339-48
pubmed: 21036955
Health Sci Rep. 2018 Jul 18;1(8):e59
pubmed: 30623094
Br J Dermatol. 2005 Feb;152(2):202-16
pubmed: 15727630
Thorax. 2006 Jan;61(1):3-5
pubmed: 16396950
Vaccines (Basel). 2020 Apr 26;8(2):
pubmed: 32357557
J Allergy Clin Immunol. 2017 Jan;139(1):166-172
pubmed: 27609659
J Allergy Clin Immunol. 2015 Jul;136(1):81-86.e4
pubmed: 25910716
J Allergy Clin Immunol. 2017 Oct;140(4):909-920
pubmed: 28987220
J Allergy Clin Immunol. 2003 Apr;111(4):847-53
pubmed: 12704368
J Allergy Clin Immunol. 2015 Jul;136(1):3-13
pubmed: 26145982
Immunol Allergy Clin North Am. 2019 Aug;39(3):391-401
pubmed: 31284928
JCI Insight. 2018 May 3;3(9):
pubmed: 29720571
Pediatr Allergy Immunol. 2013 Feb;24(1):61-5
pubmed: 23331530
J Asthma Allergy. 2018 Aug 13;11:173-180
pubmed: 30147342
J Invest Dermatol. 2019 Feb;139(2):285-292
pubmed: 30470393
Thorax. 2000 Aug;55 Suppl 1:S2-10
pubmed: 10943631
Pediatr Allergy Immunol. 2011 Mar;22(2):243-8
pubmed: 20573034
Pediatr Allergy Immunol. 2019 Sep;30(6):604-613
pubmed: 31188509
BMJ Open. 2017 Apr 3;7(4):e013034
pubmed: 28373249
Immunol Allergy Clin North Am. 2019 Aug;39(3):xv-xvi
pubmed: 31284933
J Allergy Clin Immunol. 2012 Feb;129(2):359-67, 367.e1-3
pubmed: 22035877
Cytokine. 2019 May;117:1-7
pubmed: 30772773
Int Arch Allergy Appl Immunol. 1981;64(3):314-9
pubmed: 6260689
Allergy. 2019 Mar;74(3):518-526
pubmed: 30144084
Genome Biol. 2017 Jan 19;18(1):12
pubmed: 28103897
Int J Epidemiol. 2017 Oct 1;46(5):1392-1393k
pubmed: 29040580
Int J Epidemiol. 2004 Feb;33(1):199-207
pubmed: 15075169
Immunobiology. 2007;212(6):433-9
pubmed: 17544828